{'fraction_non_alphanumeric': 0.05005561735261402, 'fraction_numerical': 0.04004449388209121, 'mean_word_length': 4.769230769230769, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].

OBJECTIVE
To evaluate the safety and efficacy of strontium-89-chloride for management of bone metastases in patients without bone pain.


METHODS
Fifty-four patients without painful bone metastases were given a single intravenous dose (1.48-2.22 MBq/kg) of strontium-89-chloride, which was repeated once or twice at the interval between 3 and 6 months.


RESULTS
The total response rate was 74.0% in these, and the response rate was significantly lower in patients with focal size>2 cm than in those with focal size<or=2 cm (33.3% vs 66.6%, chi2=14.9, P<0.01). The side effects of strontium-89-chloride included mainly thrombocytopenia and neutropenia, mostly mild and reversible without interventions.


CONCLUSION
Strontium-89-chloride is effective and safe for treatment of nonpainful bone metastases.